Appropriate Use of FDG-PET

The purpose of this publication is to develop a consensus based on evidence from existing systematic reviews, to make health care providers aware of the value and the appropriateness of the introduction of positron emission tomography (PET), either alone or in combination with computed tomography (PET/CT) using 2-fluoro-2-deoxy-D-glucose (FDG) labelled with 18F, in the management of patient affected by cancer.

1. INTRODUCTION
- 1.1. Background
- 1.2. Objective
- 1.3. Search strategy
- 1.4. Definitions of the appropriateness criteria for the use of PET
- 1.5. Definitions of indications for PET scanning
- 1.6. Structure
2. CLINICAL SCENARIOS FOR FDG-PET/CT INDICATIONS
- 2.1. Summary of results
3. NON-SMALL CELL LUNG CANCER (NSCLC)
- 3.1. Diagnosis
- 3.2. Staging
- 3.3. Response evaluation
- 3.4. Restaging
- 3.5. Suspected recurrence
- 3.6. Follow-up
- 3.7. RT planning
4. SMALL CELL LUNG CANCER (SCLC)
- 4.1. Diagnosis
- 4.2. Staging
- 4.3. Response evaluation
- 4.4. Restaging
- 4.5. Suspected recurrence
- 4.6. Follow-up
- 4.7. RT planning
5. LYMPHOMA
- 5.1. Diagnosis
- 5.2. Staging
- 5.3. Response evaluation
- 5.4. Restaging
- 5.5. Suspected recurrence
- 5.6. Follow-up
- 5.7. RT planning
6. BREAST CANCER
- 6.1. Diagnosis
- 6.2. Staging
- 6.3. Response evaluation
- 6.4. Restaging
- 6.5. Suspected recurrence
- 6.6. Follow-up
- 6.7. RT planning
7. MELANOMA
- 7.1. Diagnosis
- 7.2. Staging
- 7.3. Response evaluation
- 7.4. Restaging
- 7.5. Suspected recurrence
- 7.6. Follow-up
- 7.7. RT planning
8. OVARIAN CANCER
- 8.1. Diagnosis
- 8.2. Staging
- 8.3. Response evaluation
- 8.4. Restaging
- 8.5. Suspected recurrence
- 8.6. Follow-up
- 8.7. RT planning
9. CANCER OF THE UTERUS AND CERVIX
- 9.1. Diagnosis
- 9.2. Staging
- 9.3. Response evaluation
- 9.4. Restaging
- 9.5. Suspected recurrence
- 9.6. Follow-up
- 9.7. RT planning
10. HEAD AND NECK CANCERS
- 10.1. Diagnosis
- 10.2. Staging
- 10.3. Response evaluation
- 10.4. Restaging
- 10.5. Suspected recurrence
- 10.6. Follow-up
- 10.7. RT planning
11. KIDNEY CANCER
- 11.1. Diagnosis
- 11.2. Staging
- 11.3. Response evaluation
- 11.4. Restaging
- 11.5. Suspected recurrence
- 11.6. Follow-up
- 11.7. RT planning
12. GERMINAL TUMOURS
- 12.1. Diagnosis
- 12.2. Staging
- 12.3. Response evaluation
- 12.4. Restaging
- 12.5. Suspected recurrence
- 12.6. Follow-up
- 12.7. RT planning
13. CANCER OF UNKNOWN PRIMARY (CUP)
- 13.1. Diagnosis
- 13.2. Staging
- 13.3. Response evaluation
- 13.4. Restaging
- 13.5. Suspected recurrence
- 13.6. Follow-up
- 13.7. RT planning
14. COLORECTAL CANCER
- 14.1. Diagnosis
- 14.2. Staging
- 14.3. Response evaluation
- 14.4. Restaging
- 14.5. Suspected recurrence
- 14.6. Follow-up
- 14.7. RT planning
15. GASTRIC CARCINOMA
- 15.1. Diagnosis
- 15.2. Staging
- 15.3. Response evaluation
- 15.4. Restaging
- 15.5. Suspected recurrence
- 15.6. Follow-up
- 15.7. RT planning
16. SARCOMAS (SOFT TISSUE AND BONE)
- 16.1. Diagnosis
- 16.2. Staging
- 16.3. Response evaluation
- 16.4. Restaging
- 16.5. Suspected recurrence
- 16.6. Follow-up
- 16.7. RT planning
17. PRIMARY TUMOURS OF THE CENTRAL NERVOUS SYSTEM
- 17.1. Diagnosis
- 17.2. Staging
- 17.3. Response evaluation
- 17.4. Restaging
- 17.5. Suspected recurrence
- 17.6. Follow-up
- 17.7. RT planning
18. NASOPHARYNGEAL CARCINOMAS
- 18.1. Diagnosis
- 18.2. Staging
- 18.3. Response evaluation
- 18.4. Restaging
- 18.5. Suspected recurrence
- 18.6. Follow-up
- 18.7. RT planning
19. GASTROINTESTINAL STROMAL TUMOURS (GISTS)
- 19.1. Diagnosis
- 19.2. Staging
- 19.3. Response evaluation
- 19.4. Restaging
- 19.5. Suspected recurrence
- 19.6. Follow-up
- 19.7. RT planning
20. PANCREATIC ADENOCARCINOMA
- 20.1. Diagnosis
- 20.2. Staging
- 20.3. Response evaluation
- 20.4. Restaging
- 20.5. Suspected recurrence
- 20.6. Follow-up
- 20.7. RT planning
21. CHOLANGIO- AND GALLBLADDER CARCINOMAS
- 21.1. Diagnosis
- 21.2. Staging
- 21.3. Response evaluation
- 21.4. Restaging
- 21.5. Suspected recurrence
- 21.6. Follow-up
- 21.7. RT planning
22. OESOPHAGEAL CANCER
- 22.1. Diagnosis
- 22.2. Staging
- 22.3. Response evaluation
- 22.4. Restaging
- 22.5. Suspected recurrence
- 22.6. Follow-up
- 22.7. RT planning
23. THYROID CANCER
- 23.1. Diagnosis
- 23.2. Staging
- 23.3. Response evaluation
- 23.4. Restaging and suspected recurrence
- 23.5. Follow-up
- 23.6. RT planning
CONTRIBUTORS TO DRAFTING AND REVIEW

Shortcuts

Latest
Events
Links
General Public Information
Databases & Statistics
IAEA Publications

Appropriate Use of FDG-PET

Contents